Latest News - Clinical Trials

Wednesday, March 22, 2017 | Clinical Trials, Management/Leadership

ClarVista Medical Completes Milestone to Advance Novel Modular Intraocular Lens for Cataract Lens Replacement

ClarVista Medical, a privately-held ophthalmic device company developing the Harmoni Modular IOL System, a novel IOL used to restore vision after cataract surgery, announced that several feasibility t…

Read the full story

Tuesday, March 21, 2017 | Clinical Trials, Partnerships

Nemus Bioscience Signs Agreement with Nanomerics to Advance NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

Nemus Bioscience announced that the company has signed a development agreement with Nanomerics of the United Kingdom to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinat…

Read the full story

Monday, March 20, 2017 | Clinical Trials, Retina

NightstaRx Commences First Phase 1/2 Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa

NightstaRx, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announces that the company has commenced enrolling and dosing subjects in a p…

Read the full story

Monday, March 13, 2017 | Clinical Trials, Retina

BioTime Expands OpRegen Clinical Trial in Dry AMD With Opening of First US Sites

BioTime announced the expansion of its ongoing phase 1/2a clinical trial for OpRegen in the advanced dry form age-related macular degeneration (AMD) by naming the first two sites that will treat patie…

Read the full story

Thursday, March 09, 2017 | Clinical Trials

Opthea Completes FDA Meeting to Inform OPT-302 Wet AMD Clinical Program

Opthea has completed a type C meeting with the FDA to obtain regulatory guidance on the clinical development program and proposed phase 2B clinical trial of OPT-302, Opthea's novel VEGF-C/D 'T…

Read the full story

Thursday, March 09, 2017 | Clinical Trials, Nicox

Nicox Resubmits AC-170 (Zerviate) NDA for Allergic Conjunctivitis Drug Candidate

Nicox announced the resubmission of the new drug application (NDA) for AC-170, its novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conj…

Read the full story

Wednesday, March 01, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa

Aerie Pharmaceuticals announced that it resubmitted its new drug application (NDA) for Rhopressa to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, …

Read the full story

Thursday, February 23, 2017 | Clinical Trials, Medical Studies

ToolGen Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System In Vivo Genome Editing

ToolGen announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo, according to a …

Read the full story

Tuesday, February 21, 2017 | Clinical Trials, Nicox

Nicox Presents NCX 667 Scientific Data at AOPT 2017

Nicox SA announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientif…

Read the full story

Friday, February 17, 2017 | Clinical Trials, Product Releases, Pixium Vision

Pixium Vision Announces First Implantation and Activation of IRIS II in Spain

Pixium Vision announced the first implantation and activation of IRIS II in Spain. This implantation is part of Pixium Vision’s ongoing multicenter clinical trial to assess the performance of IR…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With RVO

Clearside Biomedical announced the enrollment of the first patient in a phase 3 clinical trial (SAPPHIRE) of Zuprata, its proprietary suspension formulation of the corticosteroid triamcinolone acetoni…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Tuesday, February 14, 2017 | Clinical Trials

Regenxbio Announces IND Active for Phase 1 Trial of RGX-314 to Treat Wet AMD

Regenxbio announced the investigational new drug (IND) application is active for the planned multicenter, open-label, multiple-cohort, dose-escalation phase 1 clinical trial of RGX-314 for the treatme…

Read the full story

Thursday, February 09, 2017 | Clinical Trials

Iconic Therapeutics to Present Phase 2a EMERGE Trial Results

Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced that the res…

Read the full story

Monday, February 06, 2017 | Clinical Trials

Aura Biosciences Receives FDA Clearance of Investigational NDA for Light-Activated AU-011 for the Treatment of Ocular Melanoma

Aura Biosciences announced that the FDA has cleared the investigational new drug application (IND) for the company’s lead program, light-activated AU-011 in ocular melanoma. This active IND enab…

Read the full story
Load More